Company intelligence / Profile preview

HotSpot Therapeutics

Cambridge, Massachusetts, United Stateshotspotthera.com ↗

Ownership: Private
Development stage: Phase 2

Overview

HotSpot Therapeutics has advanced its lead program HST–1011—a novel allosteric inhibitor of CBL-B—into Phase 1 clinical trials with first-in-human data presented at ESMO Congress in September 2024. The company also has preclinical programs targeting IRF5 for autoimmune disorders and MALT1 for hematologic malignancies and solid tumors. Its approach enables the targeting of previously undruggable proteins by exploiting natural regulatory “hotspots” using proprietary allosteric chemistry.

Therapeutic areas: OncologyMetabolic DisordersRheumatology
Modalities: small molecules (allosteric inhibitors)
Industry: Biotech

Drug pipeline

5 assets

HST-1011

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on HotSpot Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HotSpot Therapeutics.

Explore the full profile